Demographics, clinical characteristics and hematological findings in the study population.

<p>Data are presented as the number of subjects in each group, with percentages given in parentheses or mean, with SD given in parentheses.</p><p>^a Date were collected at the onset of IFD and bacterial sepsis, or about postnatal age of 21 days for preterm control infants.</p><p>^bComparison between IFD vs preterm control <i>p</i><0.05</p><p>^cComparison between IFD vs bacterial sepsis <i>p</i><0.05</p><p>^dComparison between bacterial sepsis vs preterm control <i>p</i><0.05</p><p>Demographics, clinical characteristics and hematological findings in the study population.</p

Receiver operating characteristic curves for the diagnosis of IFD by four platelet parameters.

<p>For each indicator, sensitivity (true positive rate) is plotted against 1-specificity (false positive rate). Accuracy is measured by the area under the ROC curve. Platelet count (PC) and plateletcrit (PCT) showed better accuracy than platelet distribution width (PDW) and hemoglobin (MPV).</p

ROC analysis for the prediction of IFD by platelet parameters using the cutoffs with the maximal sum of sensitivity and specificity.

<p>AUC = area under the curve</p><p>ROC analysis for the prediction of IFD by platelet parameters using the cutoffs with the maximal sum of sensitivity and specificity.</p

Birth, clinical characteristics and hematological findings in deceased versus survived IFD at the onset and 14 days after antifungal therapy in survived IFD infants.

<p>Data are presented as the number of subjects in each group, with percentages given in parentheses or mean, with SD given in parentheses.</p><p>^a<i>P</i>1 values compares the deceased IFD with the survived IFD.</p><p>^b<i>P</i>2 values compares hematological parameters at the onset day and at the 14^th day after antifungal treatment in the survived IFD.</p><p>Birth, clinical characteristics and hematological findings in deceased versus survived IFD at the onset and 14 days after antifungal therapy in survived IFD infants.</p

Receiver operating characteristic curves for predicting mortality in IFD infants by platelet count (PC) and plateletcrit (PCT).

<p>For each indicator, sensitivity (true positive rate) is plotted against 1-specificity (false positive rate). Accuracy is measured by the area under the ROC curve. The AUCs for PC and PCT were 0.775 (95% CI: 0.629–0.920, p = .002) and 0.765 (95% CI: 0.610–0.921, p = .006), respectively.</p

Summary of statistical values of OPLS-DA with different scaling methods for data obtained from LC-MS analyses^a.

a<p>Including the different cumulated modeled variations in X [R²X(cum)] and Y [R²Y(cum)] matrix on spectral datasets and predictability of the model [Q²(cum)].</p

OPLS-DA score scatter plots obtained from of LCMS analysis of samples.

<p>A. OPLS-DA score plots of BA and normal; B. OPLS-DA score plots of with NHS and normal; C. OPLS-DA score plots of BA and NHS; D. OPLS-DA score plots of hyperbilirubinemia and normal. The fig. showing that the two populations are well separated respectively.</p

VIP value of the potential metabolites in the differences of NHS and BA^a.

a<p>VIP: The variable importance for projection.</p

A typical LC-MS/MS spectrum of blood spots from patients.

<p>Blood samples were prepared and mass spectrometric analysis of individual sample was performed as described in “Methods” in details. Panel A shows a mass spectrum was acquired in the neutral loss scan mode. The scan was range from m/z 140 to m/z 280. It can detect most of the amino acids. Panel B shows a mass spectrum was acquired in the multiple reaction monitor mode. It was mainly used to detect Gly, Orn, Arg, Cit and its internal standard. Panel C shows a mass spectrum was acquired in precursor ion scanning mode. It used to detect the acylcarnitine in the sample.</p

Comparison of clinical data among four groups.

<p>¹χ2-test.</p>2<p>one-way ANOVA followed by a LSD Test.</p>a<p>Comparison vs normal group p<0.05.</p>b<p>Comparison vs hyperbilirubinemia and normal group p<0.05.</p>c<p>Comparison vs NHS group, hyperbilirubinemia and normal group p<0.05.</p